Generic Drug Industry Scandal: Convicted FDA Reviewer Is Freed From Debarment
This article was originally published in The Pink Sheet Daily
Executive Summary
Twenty-five years after he pled guilty to taking payments from companies, former FDA review chemist David Brancato gets FDA to terminate his debarment; several industry execs won terminations years ago.
You may also be interested in...
Former Generic Industry Exec Who Went Undercover For DOJ No Longer Debarred
US FDA chief scientist said former exec, who was part of the generic drug scandal, deserves special termination of 1993 debarment due to his 'substantial assistance' to the DOJ in its investigations of others. Office of Regulatory Affairs wanted to deny his petition.
Insider Trading Bull's-Eye: FDA Chemist Charged With Using Agency's DARRTS NDA Tracking System For Improper Trades
A criminal complaint charges Cheng Yi Liang with trading in the securities of five companies based on the status of their new drug applications, gaining more than $2 million.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.